Literature DB >> 9412773

Therapy for lowering lipoprotein (a) levels.

B Angelin1.   

Abstract

Elevated levels of lipoprotein (a), a complex between apolipoprotein (a) and LDL, indicate an increased risk of atherosclerosis and cardiovascular disease. The important genetic regulation of lipoprotein (a) is now relatively well understood, but the progress in finding ways of influencing plasma lipoprotein (a) has been disappointingly slow. Nicotinic acid, pharmacological doses of sex hormones and anabolic steroids, as well as LDL apheresis may provide sufficient lowering of lipoprotein (a) for the evaluation of clinical response. Presently, the most important aspect is to take an evaluated lipoprotein (a) level into consideration when deciding to institute particularly aggressive lipid lowering treatment in a given individual.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9412773     DOI: 10.1097/00041433-199712000-00003

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  3 in total

Review 1.  [Angiology update].

Authors:  C Ranke; H J Trappe
Journal:  Med Klin (Munich)       Date:  1999-05-15

2.  Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway.

Authors:  Taewoo Cho; Yoojin Jung; Marlys L Koschinsky
Journal:  J Biol Chem       Date:  2008-09-05       Impact factor: 5.157

3.  Novel cardiac-specific biomarkers and the cardiovascular continuum.

Authors:  Efstathios Vassiliadis; Natasha Barascuk; Athanasios Didangelos; Morten A Karsdal
Journal:  Biomark Insights       Date:  2012-05-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.